Prostatype Genomics
Prostatype Genomics publishes Annual Report for 2023
Prostatype Genomics AB today publishes the Annual Report for the financial year of 2023. The Annual Report (Swedish) is attached as a PDF and is available on the company's webpage: www.prostatypegenomics.com
The English version of the Annual Report will be available to downloaded from the company’s webpage within shortly.
For more information, please contact:
Fredrik Rickman (previously Persson), CEO Prostatype Genomics AB
Telephone: +46 (0) 73 049 77 01
e-mail: fredrik.persson@prostatypegenomics.com
About Prostatype Genomics AB
Prostatype® is a genetic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or non-treatment of prostate cancer. The test was developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB. The Company’s Certified Adviser is Carnegie Investment Bank AB.
| Datum | 2024-04-25, kl 13:31 |
| Källa | MFN |
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!